Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption. Twenty-nine patients with a median a...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Garcia-Manero, Guillermo, Assouline, Sarit, Cortes, Jorge, Estrov, Zeev, Kantarjian, Hagop, Yang, Hui, Newsome, Willie M., Miller, Wilson H., Rousseau, Caroline, Kalita, Ann, Bonfils, Claire, Dubay, Marja, Patterson, Tracy-Ann, Li, Zuomei, Besterman, Jeffrey M., Reid, Gregory, Laille, Eric, Martell, Robert E., Minden, Mark
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2008
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081529/
https://ncbi.nlm.nih.gov/pubmed/18495956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-10-115873
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky